MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Home・Stock List・Atossa Genetics Inc

Atossa Genetics Inc

Closed

0.93 5.68

Buy Sell

Overview

Share price change

24h

Current

Min

0.85

Max

0.96

Key metrics
By Trading Economics
Income	-371K -6.7M
Employees	15
EBITDA	-766K -7.1M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+532.58% upside

Dividends
By Dow Jones
Next Earnings	11 Aug 2025

Market Stats
By TradingEconomics
Market Cap	1.6M 110M
Previous open	-4.75
Previous close	0.93

Technical Score

By Trading Central

Confidence

Bullish Evidence

0.7955 / 0.898 Support & Resistance

Atossa Genetics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 Jul 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

FCC Approves U.S. Cellular Sale to T-Mobile

11 Jul 2025, 17:28 UTC

Major Market Movers

SharpLink Gaming Gains on Ethereum Purchase

11 Jul 2025, 16:57 UTC

Earnings

BASF Cuts Outlook on Global Economy Uncertainty

11 Jul 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 Jul 2025, 19:46 UTC

Acquisitions, Mergers, Takeovers

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 Jul 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 Jul 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 Jul 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 Jul 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 Jul 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 Jul 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11 Jul 2025, 16:42 UTC

Earnings

BASF Cuts Outlook on Global Economic Uncertainty

11 Jul 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 Jul 2025, 16:05 UTC

Earnings

BASF Will Publish Half-Year Results on July 30

11 Jul 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11 Jul 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 Jul 2025, 16:03 UTC

Earnings

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 Jul 2025, 16:02 UTC

Earnings

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 Jul 2025, 16:01 UTC

Earnings

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 Jul 2025, 16:00 UTC

Earnings

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 Jul 2025, 15:59 UTC

Earnings

BASF Cuts 2025 Earnings View

11 Jul 2025, 15:58 UTC

Earnings

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 Jul 2025, 15:57 UTC

Earnings

BASF 2Q EBIT Before Special Items EUR810M

11 Jul 2025, 15:54 UTC

Earnings

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 Jul 2025, 15:54 UTC

Earnings

BASF 2Q Sales Fell 2.1% on Year

11 Jul 2025, 15:53 UTC

Earnings

BASF 2Q Sales EUR15.77B

11 Jul 2025, 15:52 UTC

Earnings

BASF: This Was in Line With Consensus Estimates

11 Jul 2025, 15:52 UTC

Earnings

BASF 2Q Ebitda Before Special Items EUR1.77B

11 Jul 2025, 15:49 UTC

Earnings

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 Jul 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer Comparison

Price change

Atossa Genetics Inc Forecast

Price Target

By TipRanks

532.58% upside

12 Months Forecast

Average 5.63 USD 532.58%

High 7.5 USD

Low 4 USD

Based on 4 Wall Street analysts offering 12 month price targets forAtossa Genetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Atossa Genetics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.7955 / 0.898Support & Resistance

Recent bullish events outweigh bearish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Atossa Genetics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.